8-K
filed June 7, 2023, 7:59 PM ET
ticker XERS
CIK 0001867096
other
confidence high
sentiment neutral
materiality 0.10
Xeris Biopharma stockholders elect three Class II directors and ratify E&Y as auditor at 2023 annual meeting
Xeris Biopharma Holdings, Inc.
- Dawn Halkuff elected with 53.2M for, 4.4M withhold, 31.2M broker non-votes.
- John Johnson elected with 42.9M for, 14.7M withhold, 31.2M broker non-votes.
- Jeffrey Sherman elected with 51.3M for, 6.3M withhold, 31.2M broker non-votes.
- Ratification of Ernst & Young as auditor approved: 87.8M for, 0.8M against, 0.2M abstain.
- No other matters were submitted to a vote at the meeting.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.99
Xeris Biopharma Holdings, Inc. shareholders approved To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-07 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-07
Exact text from the filing
The Company’s stockholders approved Proposal 2. The votes cast at the Annual Meeting were as follows*: For Against Abstain 87,826,099 820,583 239,701
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.99
Xeris Biopharma Holdings, Inc. shareholders approved To elect Dawn Halkuff, John Johnson and Jeffrey Sherman as Class II directors at the 2023-06-07 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-07
Exact text from the filing
The Company held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 7, 2023.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.